Tofacitinib — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

10 Recruiting

6 Completed trials

18 Sponsors

15 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 4 Phase II/III: 1 Phase II: 3 Phase III/IV: 2 Phase IV: 10

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Juvenile idiopathic arthritis 3 Axial spondyloarthritis 1 Rheumatoid arthritis 1 Psoriatic arthropathy 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Nantes 2 Pfizer Inc. 2 Aarhus University Hospital 1 Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Regional De Marseille 1 Centre Hospitalier Universitaire Amiens Picardie 1 Charite Universitaetsmedizin Berlin KöR 1 Duke Clinical Research Institute 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz 1 IRCCS Istituto Giannina Gaslini 1 Les Hopitaux Universitaires De Strasbourg 1

All trials

20 total

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Phase II 5 countries Centre Hospitalier De Versailles
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WIT… Pending

2024-517314-15-00 Phase III/IV 1 country Centre Hospitalier Universitaire Amiens Picardie
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending

2025-520923-25-00 Phase III 3 countries Duke Clinical Research Institute
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting

2023-509694-22-00 Phase III 10 countries Pfizer Inc.
Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine Recruiting

2024-518190-34-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases Recruiting

2025-520757-36-00 Phase IV 1 country Sint Maartenskliniek Stichting
JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting

2023-509788-25-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis… Recruiting

2023-506628-98-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) … Recruiting

2024-517865-17-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Effect of Tofacitinib on coagulation and platelet function, and its role in thromboembolic events Recruiting

2024-518434-83-01 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting

2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLAN… Ended

2023-505050-18-00 Phase IV 4 countries Charite Universitaetsmedizin Berlin KöR
Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended

2022-500599-79-00 Phase II 1 country Aarhus University Hospital
Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis. Ended

2024-518577-34-00 Phase IV 1 country Universita' Degli Studi Di Roma Tor Vergata
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA). Ended

2024-511401-40-00 Phase IV 1 country UZ Leuven
A Long-Term, Open-Label, Study for Treatment of JIA Ended

2023-509651-14-00 Phase II/III 3 countries Pfizer Inc.
TOFA-PREDICT Ended

2024-510903-12-00 Phase IV 1 country Universitair Medisch Centrum Utrecht

Showing 1–20 of 20 trials

← All drugs A–Z